Tesamorelin Reduces Belly Fat and Liver Fat in HIV Patients: Meta-Analysis of Trials
A meta-analysis of RCTs confirms tesamorelin, a GHRH analogue, significantly reduces visceral and hepatic fat in HIV-associated lipodystrophy with an acceptable safety profile.
Quick Facts
What This Study Found
Tesamorelin significantly reduces visceral and hepatic fat in HIV-associated lipodystrophy versus placebo across randomized controlled trials.
Key Numbers
How They Did This
Systematic review and random-effects meta-analysis of RCTs evaluating tesamorelin vs. placebo in adults with HIV; PubMed, Embase, Scopus, Web of Science, CENTRAL searched through July 2025.
Why This Research Matters
HIV-associated lipodystrophy causes significant morbidity and cardiovascular risk. Tesamorelin provides targeted therapy for a condition with few effective treatments.
The Bigger Picture
As people with HIV live longer, managing metabolic complications like lipodystrophy becomes increasingly important for long-term health and quality of life.
What This Study Doesn't Tell Us
Limited number of available RCTs; mostly short to medium-term follow-up; HIV-specific population limits generalizability.
Questions This Raises
- ?What are the long-term effects of tesamorelin beyond trial durations?
- ?Could tesamorelin benefit non-HIV lipodystrophy populations?
Trust & Context
- Key Stat:
- Significant VAT and hepatic fat reduction Tesamorelin vs. placebo across randomized trials in HIV lipodystrophy
- Evidence Grade:
- Meta-analysis of RCTs — strong evidence level for this specific population and outcome.
- Study Age:
- Published 2026 in Obesity Research & Clinical Practice. Searches through July 2025.
- Original Title:
- Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
- Published In:
- Obesity research & clinical practice, 20(1), 2-12 (2026)
- Database ID:
- RPEP-14810
Evidence Hierarchy
Frequently Asked Questions
What is HIV lipodystrophy?
It's a condition in HIV patients where fat accumulates in the belly and around organs (visceral fat) while being lost from the face and limbs. It increases cardiovascular risk and causes body image distress.
How does tesamorelin work?
Tesamorelin stimulates the body's own growth hormone release, which helps break down visceral (belly) fat and reduce liver fat accumulation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14810APA
Badran, Ahmed Samy; Helal, Abdulrhman; Shata, Karim Samir; Ayesh, Hazem. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.. Obesity research & clinical practice, 20(1), 2-12. https://doi.org/10.1016/j.orcp.2026.01.002
MLA
Badran, Ahmed Samy, et al. "Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.." Obesity research & clinical practice, 2026. https://doi.org/10.1016/j.orcp.2026.01.002
RethinkPeptides
RethinkPeptides Research Database. "Body composition, hepatic fat, metabolic, and safety outcome..." RPEP-14810. Retrieved from https://rethinkpeptides.com/research/badran-2026-body-composition-hepatic-fat
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.